GEIGER JESSE J

MEDP President Geiger sells 31,707 shares for $14.4M; reduces stake by -67.9% to 15,000 shares post-transaction.

Jesse J. Geiger, President of Medpace Holdings, sold 31,707 shares at $455.30 on 2026-03-17 for $14,436,197.10, reducing his holdings from 46,707 shares to 15,000 shares—a substantial -67.9% reduction. The transaction occurred while MEDP trades at $460.92, within the 52-week range of $277.23–$620.59 but notably -25.7% from the 52-week high; over 90 days the stock declined -18.9%. Within his ticker-specific history at MEDP, Geiger has 5 prior trades with mixed timing outcomes: 3 of 5 prior sells achieved negative 90-day returns (well-timed), while his cross-ticker track record across 6 prior sells shows an average 90-day return of +1.8% and a 66.67% well-timed rate. The company shows solid fundamentals with $659.9M in latest quarterly revenue, net income of $111.1M, annual revenue growth of +20.0%, and a P/E of 27.27. The magnitude of this sale—disposing of nearly two-thirds of his prior stake—represents a meaningful shift in his personal equity exposure to the company where he serves as President.

MEDP president sold 21,503 shares ($12.8M) at $595.66; reduces holdings 58.9% to 15,000 shares as stock hits 52-week high.

On 2025-11-05, GEIGER JESSE J sold 21,503 shares of Medpace Holdings at $595.66, a transaction worth $12,808,476.98 that reduced his holdings from 36,503 to 15,000 shares—a 58.9% reduction. The sale occurred near the stock's 52-week high of $605.20, only -2.6% below the peak. Geiger's cross-ticker track record shows 5 prior sells with a 66.67% well-timed rate at the 90-day mark; at MEDP specifically, 2 of 3 prior measurable sales were well-timed (negative 90d returns after the sales), though his most recent MEDP sales on 2025-10-29 and 2025-10-27 are too recent to assess. The company's fundamentals remain robust: $659.9M quarterly revenue with +11.8% annual growth and $111.1M net income, though the P/E of 38.33 reflects elevated valuation expectations. The sharply elevated 30-day and 90-day price appreciation (+11.0% and +35.6% respectively) suggests strong recent momentum into this sale point.

President GEIGER sells 23,028 shares for $13.9M at $602.00 avg, reducing stake 38.7%; stock up 16.7% in 30 days, 36.8% in 90 days

Jesse J. Geiger, President of Medpace Holdings, executed 2 separate sales totaling 23,028 shares for $13,862,915.20 on October 27–29, 2025, reducing his holdings from 59,531 shares to 36,503 shares (a -38.7% reduction). The sales occurred near the 52-week high of $605.20, with execution prices of $605.12 and $585.00 against a current price of $584.57. The stock has appreciated 16.7% over the trailing 30 days and 36.8% over the trailing 90 days. Geiger's cross-ticker track record shows 3 prior open-market sells with an average 90-day return of +5.0% and a 66.67% well-timed rate, while his same-ticker history at MEDP shows 2 of 3 prior sales were well-timed at the 90-day mark. The company shows strong fundamentals—revenue of $659,903,000.00, net income of $111,135,000.00, annual revenue growth of +11.8%, and a P/E of 38.03 at a $16,466,298,119.11 market cap. The scale and timing of this sale merit observation given the outsized recent price momentum and the insider's demonstrated timing acuity on prior MEDP sales, though the company's current growth metrics remain robust.

President Jesse Geiger sold 41,801 shares of MEDP for $18,940,451.11, reducing his stake by -53.4% to 36,503 shares.

President Jesse Geiger sold 41,801 shares of Medpace Holdings on 2025-07-24 at $453.11, totaling $18,940,451.11 and reducing his holdings to 36,503 shares (a -53.4% reduction from 78,304 shares). This is a substantial liquidation by the company's president. The stock has appreciated +45.8% in the 30 days and +47.9% in the 90 days prior to this sale, trading near its 52-week high of $477.73. Over Geiger's entire cross-ticker track record, his two prior sells exhibited a 100.00% well-timed rate at the 90-day mark, and his same-ticker history at MEDP shows 2 of 2 prior sells were also well-timed at 90 days, suggesting a consistent pattern. The company's fundamentals remain solid with $603.3M in latest-quarter revenue, $90.3M in net income, and +11.8% annual revenue growth, paired with a P/E of 30.43. The confluence of strong recent price appreciation, near-peak valuations, and a large discretionary reduction by the president in the context of historically well-timed selling warrants investor attention to the outlook.